Abstract
The present chapter discusses the pharmacology, efficacy, and safety of two recently developed sublingual formulation of zolpidem that specifically target sleep-onset insomnia (Edluar, a standard dose of zolpidem, SL-SD) and middle-of-the-night (MOTN) insomnia (Intermezzo, a low dose of zolpidem, SL-LD). These two SL formulations are bioequivalent to the standard immediate oral release (IOR) form of zolpidem and have a comparable elimination half-life but a somewhat shorter Tmax than the standard oral form. Due to a gender effect on zolpidem metabolism, half-doses are recommended in women (i.e., 5 mg for SL-SD and 1.75 mg for SL-LD). Efficacy has been shown for SL-SD in three double-dummy crossover polysomnographic studies that could demonstrate the superiority of the acute administration of 10 mg SL-SD zolpidem over the same dose of IOR zolpidem in healthy subjects using models of transient insomnia and in patients with DSM-IV primary insomnia. Both 1.75 and 3.5 mg of SL-LD zolpidem have been found effective in 2 large placebo-controlled studies performed in DSM-IV primary insomniacs having middle-of-the-night insomnia. Most common adverse events were somnolence, fatigue, headache, and dysgeusia for SL-SD zolpidem and headache, nausea, and fatigue for SL-LD zolpidem. More generally types of adverse events for SL zolpidem were consistent with the adverse event profile of IOR zolpidem. Because of its middle-of-the-night way of administration, concern regarding the next-morning safety of the SL-LD was addressed in a highway driving performance study. Results indicate that SL-LD zolpidem 3.5 mg taken 3 h before driving may impair driving performance, but that there is a minimal risk of impairing driving performance if the drug is taken ≥ 4 h before driving. SL-SD zolpidem has been approved for the short-term treatment of sleep-onset insomnia at a dose of 10 mg in non-elderly man and at the dose of 5 mg in women or in special population including elderly patients. SL-LD zolpidem has been approved for the treatment of insomnia when MOTN awakening is followed by difficulty in returning to sleep. Recommended dosages are 3.75 mg for non-elderly man and 1.75 mg in women and in special population including elderly. It has to be stressed that, due to safety issue related to next-morning residual effects, the dose should be taken following MOTN awakenings only if the patient has at least 4 h of sleep remaining.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
American Psychiatric Association (2013) Diagnosis and statistical manual of mental disorders, 5th edn. American Psychiatric Association, Arlington
Edinger JD, Fins AI, Glenn DM, Sullivan RJ Jr, Bastian LA, Marsh GR, Dailey D, Hope TV, Young M, Shaw E, Vasilas D (2000) Insomnia and the eye of the beholder: are there clinical markers of objective sleep disturbances among adults with and without insomnia complaints? J Consult Clin Psychol 68:586–589
EdluarTM (zolpidem tartrate) sublingual tablets, CIV (2009) Prescribing information. Meda Pharmaceuticals Inc., Somerset, NJ; May 2009. http://www.edluar.com/EDLUAR-PI.pdf
Farkas RH, Unger EF, Temple R (2013) Zolpidem and driving impairment. Identifying persons at risk. N Engl J Med 369:689–691
FDA Drug Safety Communication (2013) Risk of next-morning impairment after use of insomnia drugs; FDA requires lower recommended doses for certain drugs containing zolpidem (Ambien, Ambien CR, Edluar, and Zolpimist); Jan 2013. http://www.fda.gov/Drugs/DrugSafety/ucm334033.htm
Greenblatt DJ, Harmatz JS, Roth T, Singh NN, Moline ML, Harris SC, Kapil RP (2013) Comparison of pharmacokinetic profiles of zolpidem buffered sublingual tablet and zolpidem oral immediate-release tablet: results from a single-center, single-dose, randomized, open-label crossover study in healthy adults. Clin Ther 35:604–611
Hesse LM, von Moltke LL, Greenblatt DJ (2003) Clinically important drug interactions with zopiclone, zolpidem, and zaleplon. CNS Drugs 17:513–532
Intermezzo® (zolpidem tartrate) sublingual tablets, CIV (2011) Prescribing information. Transcept Pharmaceuticals Inc., Port Richmond, CA; Nov 2011. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022328lbl.pdf
Johnson LC, Spinweber CL (1983) Good and poor sleepers differ in Navy performance. Mil Med 148:727–731
Monti JM, Pandi-Perumal SR, Langer SZ (2008) Zolpidem: its use in the treatment of sleep disorder. In: Pandi-Perumal SR, Verster JC, Monti JM, Lader M, Langer SZ (eds) Sleep disorders, diagnosis and therapeutics. Informa Healthcare, London, pp 295–323
Ohayon MM (2002) Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med Rev 6:97–111
Ohayon MM, Krystal A, Roehrs TA, Roth T, Vitiello MV (2010) Using difficulty resuming sleep to define nocturnal awakenings. Sleep Med 11:236–241
Perlis ML, Smith MT, Cacialli DO, Nowakowski S, Orff H (2003) On the comparability of pharmacotherapy and behavior therapy for chronic insomnia: commentary and implications. J Psychosom Res 54:51–59
Roth T, Hull SG, Lankford A, Rosenberg R, Scharf MB (2008a) Low-dose sublingual zolpidem tartrate is associated with dose-related improvement in sleep onset and duration in insomnia characterized by middle-of-the-night (MOTN) awakenings. Sleep 31:1277–1284
Roth T, Mayleben D, Corser BC, Singh NN (2008b) Daytime pharmacodynamic and pharmacokinetic evaluation of low-dose sublingual transmucosal zolpidem hemitartrate. Hum Psychopharmacol 23:13–20
Roth T, Krystal A, Steinberg FJ, Singh NN, Moline M (2013) Novel sublingual low-dose zolpidem tablet reduces latency to sleep onset following spontaneous middle-of-the-night awakening in insomnia in a randomized, double-blind, placebo-controlled, outpatient study. Sleep 36:189–96
Staner L, Eriksson M, Cornette F, Santoro F, Muscat N, Luthinger R, Roth T (2009) Sublingual zolpidem is more effective than oral zolpidem in initiating early onset of sleep in the post-nap model of transient insomnia: a polysomnographic study. Sleep Med 10:616–620
Staner L, Cornette F, Otmani S, Nedelec JF, Danjou P (2010a) Zolpidem in the treatment of adult and elderly primary insomnia patients. In: Monti JM, Pandi-Perumal SR, Möhler H (eds) GABA and sleep: molecular, functional and clinical aspects. Springer, New York, pp 383–411
Staner C, Joly F, Jacquot N, Vlasova ID, Nethin M, Lundqvist T, Edenius C, Staner L (2010b) Sublingual zolpidem in early onset of sleep compared to oral zolpidem: polysomnographic study in patients with primary insomnia. Curr Med Res Opin 26:1423–1431
Staner L, Danjou P, Luthringer R (2012) A new sublingual formulation of zolpidem for the treatment of sleep-onset insomnia. Expert Rev Neurother 12:141–153
Swainston Harrison T, Keating GM (2005) Zolpidem: a review of its use in the management of insomnia. CNS Drugs 19:65–80
Valente KD, Hasan R, Tavares SM, Gattaz WF (2013) Lower doses of sublingual Zolpidem are more effective than oral Zolpidem to anticipate sleep onset in healthy volunteers. Sleep Med 14:20–23
Vermeeren A, Vuurman EF, Leufkens TR, Van Leeuwen CJ, Van Oers AC, Laska E, Rico S, Steinberg F, Roth T (2014) Residual effects of low-dose sublingual zolpidem on highway driving performance the morning after middle-of-the-night use. Sleep 37:489–496
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Staner, L. (2015). Zolpidem Sublingual Formulations. In: Guglietta, A. (eds) Drug Treatment of Sleep Disorders. Milestones in Drug Therapy. Springer, Cham. https://doi.org/10.1007/978-3-319-11514-6_7
Download citation
DOI: https://doi.org/10.1007/978-3-319-11514-6_7
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-11513-9
Online ISBN: 978-3-319-11514-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)